Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.
Identifieur interne : 000252 ( PubMed/Corpus ); précédent : 000251; suivant : 000253Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.
Auteurs : Stephen Mac ; Amanda Sumner ; Samuel Duchesne-Belanger ; Robert Stirling ; Matthew Tunis ; Beate SanderSource :
- Pediatrics [ 1098-4275 ] ; 2019.
English descriptors
- KwdEn :
- Antiviral Agents (economics), Antiviral Agents (therapeutic use), Cost-Benefit Analysis (methods), Humans (MeSH), Palivizumab (economics), Palivizumab (therapeutic use), Respiratory Syncytial Virus Infections (drug therapy), Respiratory Syncytial Virus Infections (economics), Respiratory Syncytial Viruses (MeSH).
- MESH :
- chemical , economics : Antiviral Agents, Palivizumab.
- chemical , therapeutic use : Antiviral Agents, Palivizumab.
- drug therapy : Respiratory Syncytial Virus Infections.
- economics : Respiratory Syncytial Virus Infections.
- methods : Cost-Benefit Analysis.
- Humans, Respiratory Syncytial Viruses.
Abstract
CONTEXT
Palivizumab prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, because of its high cost, the value of this intervention is unclear.
OBJECTIVE
To systematically review the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants <24 months of age.
DATA SOURCES
Medline, Embase, and Cochrane Library up to August 2018.
STUDY SELECTION
Two reviewers independently screened results to include economic evaluations conducted between 2000 and 2018 from Organization for Economic Cooperation and Development countries.
DATA EXTRACTION
Two reviewers independently extracted outcomes. Quality appraisal was completed by using the Joanna Briggs Institute checklist. Costs were adjusted to 2017 US dollars.
RESULTS
We identified 28 economic evaluations (20 cost-utility analyses and 8 cost-effectiveness analyses); most were from the United States (
LIMITATIONS
Model design heterogeneity, model parameters, and study settings were barriers to definitive conclusions on palivizumab's economic value.
CONCLUSIONS
Palivizumab as RSV prophylaxis was considered cost-effective in prematurely born infants, infants with lung complications, and infants from remote communities.
DOI: 10.1542/peds.2018-4064
PubMed: 31040196
Links to Exploration step
pubmed:31040196Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.</title>
<author><name sortKey="Mac, Stephen" sort="Mac, Stephen" uniqKey="Mac S" first="Stephen" last="Mac">Stephen Mac</name>
<affiliation><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada; sm.mac@mail.utoronto.ca.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sumner, Amanda" sort="Sumner, Amanda" uniqKey="Sumner A" first="Amanda" last="Sumner">Amanda Sumner</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Duchesne Belanger, Samuel" sort="Duchesne Belanger, Samuel" uniqKey="Duchesne Belanger S" first="Samuel" last="Duchesne-Belanger">Samuel Duchesne-Belanger</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Stirling, Robert" sort="Stirling, Robert" uniqKey="Stirling R" first="Robert" last="Stirling">Robert Stirling</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tunis, Matthew" sort="Tunis, Matthew" uniqKey="Tunis M" first="Matthew" last="Tunis">Matthew Tunis</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name>
<affiliation><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute of Clinical Evaluative Sciences, Toronto, Canada; and.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31040196</idno>
<idno type="pmid">31040196</idno>
<idno type="doi">10.1542/peds.2018-4064</idno>
<idno type="wicri:Area/PubMed/Corpus">000252</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000252</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.</title>
<author><name sortKey="Mac, Stephen" sort="Mac, Stephen" uniqKey="Mac S" first="Stephen" last="Mac">Stephen Mac</name>
<affiliation><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada; sm.mac@mail.utoronto.ca.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sumner, Amanda" sort="Sumner, Amanda" uniqKey="Sumner A" first="Amanda" last="Sumner">Amanda Sumner</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Duchesne Belanger, Samuel" sort="Duchesne Belanger, Samuel" uniqKey="Duchesne Belanger S" first="Samuel" last="Duchesne-Belanger">Samuel Duchesne-Belanger</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Stirling, Robert" sort="Stirling, Robert" uniqKey="Stirling R" first="Robert" last="Stirling">Robert Stirling</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tunis, Matthew" sort="Tunis, Matthew" uniqKey="Tunis M" first="Matthew" last="Tunis">Matthew Tunis</name>
<affiliation><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name>
<affiliation><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute of Clinical Evaluative Sciences, Toronto, Canada; and.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Pediatrics</title>
<idno type="eISSN">1098-4275</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (economics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Cost-Benefit Analysis (methods)</term>
<term>Humans (MeSH)</term>
<term>Palivizumab (economics)</term>
<term>Palivizumab (therapeutic use)</term>
<term>Respiratory Syncytial Virus Infections (drug therapy)</term>
<term>Respiratory Syncytial Virus Infections (economics)</term>
<term>Respiratory Syncytial Viruses (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiviral Agents</term>
<term>Palivizumab</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Palivizumab</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Respiratory Syncytial Virus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Respiratory Syncytial Virus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cost-Benefit Analysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Respiratory Syncytial Viruses</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>CONTEXT</b>
</p>
<p>Palivizumab prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, because of its high cost, the value of this intervention is unclear.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>To systematically review the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants <24 months of age.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DATA SOURCES</b>
</p>
<p>Medline, Embase, and Cochrane Library up to August 2018.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>STUDY SELECTION</b>
</p>
<p>Two reviewers independently screened results to include economic evaluations conducted between 2000 and 2018 from Organization for Economic Cooperation and Development countries.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DATA EXTRACTION</b>
</p>
<p>Two reviewers independently extracted outcomes. Quality appraisal was completed by using the Joanna Briggs Institute checklist. Costs were adjusted to 2017 US dollars.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>We identified 28 economic evaluations (20 cost-utility analyses and 8 cost-effectiveness analyses); most were from the United States (</p>
</div>
<div type="abstract" xml:lang="en"><p><b>LIMITATIONS</b>
</p>
<p>Model design heterogeneity, model parameters, and study settings were barriers to definitive conclusions on palivizumab's economic value.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Palivizumab as RSV prophylaxis was considered cost-effective in prematurely born infants, infants with lung complications, and infants from remote communities.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31040196</PMID>
<DateCompleted><Year>2019</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>11</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1098-4275</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>143</Volume>
<Issue>5</Issue>
<PubDate><Year>2019</Year>
<Month>05</Month>
</PubDate>
</JournalIssue>
<Title>Pediatrics</Title>
<ISOAbbreviation>Pediatrics</ISOAbbreviation>
</Journal>
<ArticleTitle>Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e20184064</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2018-4064</ELocationID>
<Abstract><AbstractText Label="CONTEXT">Palivizumab prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, because of its high cost, the value of this intervention is unclear.</AbstractText>
<AbstractText Label="OBJECTIVE">To systematically review the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants <24 months of age.</AbstractText>
<AbstractText Label="DATA SOURCES">Medline, Embase, and Cochrane Library up to August 2018.</AbstractText>
<AbstractText Label="STUDY SELECTION">Two reviewers independently screened results to include economic evaluations conducted between 2000 and 2018 from Organization for Economic Cooperation and Development countries.</AbstractText>
<AbstractText Label="DATA EXTRACTION">Two reviewers independently extracted outcomes. Quality appraisal was completed by using the Joanna Briggs Institute checklist. Costs were adjusted to 2017 US dollars.</AbstractText>
<AbstractText Label="RESULTS">We identified 28 economic evaluations (20 cost-utility analyses and 8 cost-effectiveness analyses); most were from the United States (<i>n</i>
= 6) and Canada (<i>n</i>
= 5). Study quality was high; 23 studies met >80% of the Joanna Briggs Institute criteria. Palivizumab prophylaxis ranged from a dominant strategy to having an incremental cost-effectiveness ratio of $2 526 203 per quality-adjusted life-year (QALY) depending on study perspective and targeted population. From the payer perspective, the incremental cost-effectiveness ratio for preterm infants (29-35 weeks' gestational age) was between $5188 and $791 265 per QALY, with 90% of estimates <$50 000 per QALY. Influential parameters were RSV hospitalization reduction rates, palivizumab cost, and discount rate.</AbstractText>
<AbstractText Label="LIMITATIONS">Model design heterogeneity, model parameters, and study settings were barriers to definitive conclusions on palivizumab's economic value.</AbstractText>
<AbstractText Label="CONCLUSIONS">Palivizumab as RSV prophylaxis was considered cost-effective in prematurely born infants, infants with lung complications, and infants from remote communities.</AbstractText>
<CopyrightInformation>Copyright © 2019 by the American Academy of Pediatrics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mac</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada; sm.mac@mail.utoronto.ca.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sumner</LastName>
<ForeName>Amanda</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Public Health Agency of Canada, Ottawa, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Duchesne-Belanger</LastName>
<ForeName>Samuel</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Public Health Agency of Canada, Ottawa, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stirling</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Public Health Agency of Canada, Ottawa, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tunis</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Public Health Agency of Canada, Ottawa, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sander</LastName>
<ForeName>Beate</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute of Clinical Evaluative Sciences, Toronto, Canada; and.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Public Health Ontario, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Pediatrics</MedlineTA>
<NlmUniqueID>0376422</NlmUniqueID>
<ISSNLinking>0031-4005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>DQ448MW7KS</RegistryNumber>
<NameOfSubstance UI="D000069455">Palivizumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069455" MajorTopicYN="N">Palivizumab</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018357" MajorTopicYN="N">Respiratory Syncytial Virus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012136" MajorTopicYN="N">Respiratory Syncytial Viruses</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>02</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31040196</ArticleId>
<ArticleId IdType="pii">peds.2018-4064</ArticleId>
<ArticleId IdType="doi">10.1542/peds.2018-4064</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/MaghrebDataLibMedV2/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000252 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000252 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= MaghrebDataLibMedV2 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:31040196 |texte= Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:31040196" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MaghrebDataLibMedV2
![]() | This area was generated with Dilib version V0.6.38. | ![]() |